Six Peptides Are "Back." The FDA Didn't Do It, It Can Be Undone Overnight, and the Fine Print Kills the Pre-Mixed Wolverine Vial.

TL;DR

• On October 28, 2026, HHS (not FDA) released an enforcement discretion policy for six peptides: BPC-157, TB-500, KPV, MOTS-c, Semax and Epitalon. It publishes in the Federal Register today, October 30 (HHS notice, FR 2026-22192).
• It is not approval and not legalization. HHS is promising not to enforce against state-licensed 503A pharmacies, federal facilities and licensed physicians who compound these six under strict conditions. The notice says itself it "is not binding on HHS or the public."
• The conditions are the real story: FDA-registered, CGMP source manufacturer, a full lot-level certificate of analysis, one peptide per product, fixed routes (Semax intranasal only, KPV topical/oral only), and mandatory adverse-event reporting (HHS Appendix B).
• "Research use only" vials are not covered. HHS says outright the goal is to pull people away from foreign RUO supply.
• Public comments are open now on regulations.gov, docket HHS-OASH-2026-0496, for two weeks after publication (about November 13).

Last reviewed: October 30, 2026

What actually happened

In July, FDA's Pharmacy Compounding Advisory Committee voted to recommend six of seven peptides for the 503A bulks list, over the objections of FDA's own review team (our July breakdown). The normal next step is FDA rulemaking: a proposed rule, a comment period and a final rule. That takes 8 to 24 months.

That's not what happened. According to the AP, HHS first wanted FDA to write a rule declaring the peptides fit for compounding. FDA officials warned their scientists would not support a rule deeming them safe, and the plan was scaled back to this: the Secretary's office telling FDA not to enforce (AP via WKMG). Former FDA officials told AP it is extremely rare for HHS, rather than FDA, to lead on compounding policy.

So the headline "FDA won't block six peptides" is technically true. FDA didn't choose this. It was told.

Hot take #1: Enforcement discretion is a lease, not a deed

Read the notice's own language. The policy "does not establish any rights for any person and is not binding on HHS or the public." HHS "may revisit application of this interim policy (in whole or in part)" if a safety signal or quality problem shows up (HHS notice). It runs until FDA finalizes a rule on each peptide, and FDA hasn't proposed one.

That means three things can end it without warning:

1. One bad cluster of adverse events. The policy is built to collect them through MedWatch. That's the tripwire.
2. A new HHS Secretary. A policy created by a Secretary's notice can be withdrawn by the next one's notice.
3. Your state. The policy covers state-licensed pharmacies. It does not override state pharmacy boards, and the Alliance for Pharmacy Compounding has already said how it intersects with state rules needs clarifying (AP). The American Peptide Association's co-founder told Reuters some states may not follow (Reuters via KFGO).

Any clinic building a business line on this should build it like it could be gone in a quarter.

Hot take #2: This is a crackdown on the gray market dressed up as a giveaway

Everyone is reading this as "peptides are legal now." Read Appendix B and it looks more like the opposite for the cheap stuff.

HHS said it plainly: the policy is meant to discourage "research-use-only peptides supplied by foreign manufacturers" (HHS Appendix B). BakerHostetler's read is that the policy does not cover products sold as research chemicals or supplements, and that supplier verification falls largely on the compounder (BakerHostetler).

Our read: the RUO vendors celebrating this week are celebrating the wrong thing. Their product didn't get legitimized. A licensed competitor just got a lane they don't qualify for.

Hot take #3: The route list is where the hype dies

The policy covers specific salt forms and specific routes. Nothing else.

Source: HHS Appendix B

Two things jump out:

• Injectable KPV and injectable Semax are not covered. Users who run them by injection in community protocols won't find a compliant compounded version.
• Oral BPC-157 needs paperwork that may not exist. Oral products require documentation that the specific formulation achieves adequate oral bioavailability in humans. For a peptide with very little human pharmacokinetic data, that's a high bar. Don't be surprised if compliant oral BPC-157 is scarce or slow to appear.

Also missing from the list entirely: GHK-Cu, Melanotan II, LL-37, Dihexa and PEG-MGF, which are still waiting on their own advisory committee review, and emideltide (DSIP), which the July panel voted down. See the regulatory tracker for where each one stands.

Hot take #4: Access went up. The evidence didn't.

Nothing about the science changed on October 28. FDA's reviewers found no human safety studies for KPV, TB-500, MOTS-c or Epitalon, and judged the BPC-157 trials too small and short to establish safety or efficacy (FDA BPC-157 review; summarized by Peptide Briefs). A 2026 systematic review of human BPC-157 data found three studies totaling about 30 people and rated the evidence very low (Acta Orthopaedica Belgica).

And one gap stands out in the policy itself: the CoA requirement covers the raw powder, not the finished vial the pharmacy dispenses, as epidemiologist Céline Gounder pointed out (Gounder). A clean input doesn't guarantee a clean output. Ask your pharmacy whether it tests the finished product.

That's not an argument against access. It's an argument for going in with your eyes open. Most of what's known about these six still comes from animal studies and user reports. The new adverse-event reporting is, in effect, the first large human dataset, and you'd be part of it.

Who wins, who loses

What to do this week

1. If you have a view, file a comment. Docket HHS-OASH-2026-0496 on regulations.gov, open through about November 13, 2026. Two weeks is short.
2. If you're getting one of these six, get it through a prescriber and a 503A pharmacy, and ask the pharmacy for the source manufacturer and the lot CoA. Under this policy they should have both.
3. Check your state. Federal non-enforcement doesn't stop a state board from acting.
4. Report side effects. The policy depends on MedWatch reports. If something goes wrong, report it to FDA.

Bottom line

This is the biggest practical access change for these six since FDA put them in Category 2 in 2023. It's also the flimsiest legal footing possible: a Secretary's notice, issued over the objections of FDA's own scientists, that can be pulled the moment a safety signal shows up.

Our call: treat it as a regulated on-ramp, not a free-for-all. The winners will be the people and clinics who meet the sourcing bar. The RUO market didn't get a pass. It got a deadline.

FAQ

Did the FDA approve BPC-157 and the other five peptides? No. HHS's notice says the policy does not grant FDA approval or establish safety and effectiveness. It's a decision not to enforce against certain compounders who meet specific conditions.

Which six peptides are covered? BPC-157, TB-500, KPV, MOTS-c, Semax and Epitalon, each limited to a specific salt form and route.

Are research-use-only peptides legal now? No. The policy covers 503A compounding by state-licensed pharmacies, federal facilities and licensed physicians using registered, CGMP-sourced ingredients. RUO products are not covered, and HHS says the policy aims to discourage them.

Can a pharmacy compound a BPC-157 and TB-500 blend? Not under this policy. Each product can contain only one active ingredient from the list.

Is injectable KPV or Semax covered? No. KPV is covered for topical and oral use only, and Semax for intranasal use only.

How long does the policy last? It runs until FDA finalizes a rule on each peptide, but HHS can revise or withdraw it at any time, especially if safety or quality problems appear.

How do I comment? On regulations.gov under docket HHS-OASH-2026-0496. Comments are due two weeks after the October 30 Federal Register publication.

Disclosure: The Peptide Dispatch shares common ownership with 1836 Wellness, a Houston medical clinic. This article is educational, reports what regulators, studies and news outlets have said, and is not medical or legal advice or a recommendation to use any substance. None of these six peptides is FDA-approved for any use.